$HALB Offers Alt-Path for Reopening Trade with Strong Bearing

OTC:HALB   Halberd Corp
HALB is positioned as an alternative to traditional vaccine solutions, which is a rare narrative, potentially conferring scarcity value on shares (contingent on efficacy and execution.

The company that holds the exclusive rights to a number of COVID-19 “extracorporeal treatment” technology provisional patent applications ("Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus," and, "Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans," "Nasal Spray to Prevent the Transmission of Covid-19," and "Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus").


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.